Chardan Capital Initiates Coverage On Editas Medicine(EDIT). In a research note issued to the investors, the brokerage major Announces the price-target to $65 per share. The shares have been rated Buy. The rating by the stock financial advisor at Chardan Capital was issued on Mar 28, 2017 in a research report to their Investors and Clients.
Editas Medicine (EDIT) shares turned negative on Fridays trading session with the shares closing down -0.01 points or -0.05% at a volume of 12,41,558. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $20.3364. The peak price level was also seen at $20.3364 while the days lowest was $18.6997. Finally the shares closed at $19.26. The 52-week high of the shares is $43.5 while the 52-week low is $12.43. According to the latest information available, the market cap of the company is $707 M.
Editas Medicine(EDIT) last announced its earnings results on Mar 7, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $898.000K. Analysts had an estimated revenue of $1.460M. Earnings per share were $-1.1. Analysts had estimated an EPS of $-0.62.
Several Insider Transactions has been reported to the SEC. On Mar 17, 2017, Alexandra Glucksmann (Chief Operating Officer) sold 1,000 shares at $26.41 per share price.Also, On Feb 16, 2017, Andrew A. F. Hack (Chief Financial Officer) sold 3,000 shares at $19.20 per share price.On Dec 8, 2016, Kevin Bitterman (director 10% owner) sold 75,000 shares at $15.82 per share price, according to the Form-4 filing with the securities and exchange commission.